Skip to main content
. 2018 Jun 15;70(8):1256–1264. doi: 10.1002/art.40511

Figure 2.

Figure 2

A, Systemic Lupus Erythematosus Responder Index 4 (SRI‐4) response over time in the patients treated with placebo (n = 108) and those treated with subcutaneous (SC) belimumab 200 mg (n = 248). B, Post hoc analysis of SRI‐5 through SRI‐8 response over time in the patients treated with placebo (n = 108) and those treated with SC belimumab 200 mg (n = 246). The definitions of SRI‐5 through SRI‐8 were the same as that of SRI‐4, except with increasingly higher thresholds for Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index score reduction (5–8 points). * = P ≤ 0.05; † = P ≤ 0.01; ‡ = P ≤ 0.001; § = P ≤ 0.0001, versus placebo.